print small

Participating Countries:

Algeria

Argentina

Australia

Austria

Belgium

Bosnia and Herzegovina

Bulgaria

Croatia

Czech Republic

Denmark

Finland

France

FYR of Macedonia

Germany

Greece

Iceland

Ireland

Israel

Italy

Lithuania

Morocco

Netherlands

New Zealand

Poland

Portugal

Romania

Russian Federation

Serbia

Slovenia

Spain

Sweden

Switzerland

Turkey

Ukraine

United Kingdom

United States

Member area provided by LTFE
COST is supported by the EU Framework Programme Horizon 2020
This website is supported by COST

Antitumor effectiveness of antiangiogenic therapy in murine B16-F1 melanoma

STSM by Natasa Tesic, PhD Student

Period of mission: from 01/09/2013 to 29/11/2013

Home institution: University of Primorska, Faculty of Health Sciences, Izola, Slovenia

Host institution: Université Catholique de Louvain, Louvain Drug Research Institute, Brussels, Belgium

The aims of STSM were (i) to evaluate antitumor effect of antiangiogenic therapy in murine B16 F1 melanoma by intra-tumoral electrotransfer of plasmid encoding endothelial specific promoter-driven short interfering RNA directed to the endoglin (ii) to investigate immune response against endoglin after electrotransfer of DNA vaccines coding for murine and porcine endoglin and to confirm efficacy of immunization by challenging mice with B16 F1 melanoma cells. To determine antitumor effect of antiangiogenic therapy, tumors were transfected with plasmids encoding tissue specific or constitutive eukaryotic promoter-driven siRNA directed to endoglin, using electroporation. Negative control was plasmid encoding constitutive cytomegalovirus promoter-drive luciferase. Tumor growth was followed and tumors were removed at day 7 post-treatment to determine intra-tumoral levels of endoglin mRNA. Two DNA vaccines encoding murine and porcine endoglin were successfully constructed and C57BL/6 mice, were immunized by intramuscular electroporation. For determination of antibodies against endoglin, blood samples were collected 3 days before each vaccine delivery. Two weeks after last boost mice were challenged with B16 F1 melanoma cells. Single electrotransfer of antiangiogenic plasmids in B16 F1 tumors didn’t resulted in significantly prolonged growth delays and survival rates, compared to the negative control. Results of qRT PCR showed that there was no reduction of mRNA endoglin expression level in tumors treated with plasmids compared to the untreated control. For analysis of blood serum, is still necessary to optimize protocol for ELISA assay. Efficacy of immunization after challenge with B16 F1 melanoma cells will be confirmed by following tumor growth and survival rate.

Oral presentation(s) originating from this mission

Event 1st World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies
Location Portorož/Slovenia
Period 06/09 - 10/09/2015
Authors Maja Čemažar, Tanja Dolinšek, Natasa Tešić, Monika Štimac, Gregor Serša
Title Electrotransfer of antiangiogenic shRNA against endoglin for effective cancer treatment

 


Project Office

Working groups

Steering Committee

Founding members

DC Rapporteurs

Related sites: